India Multiomics Market Size, Share, Growth, and Industry Analysis, By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics) and Forecast, 2026-2034

India Multiomics Market Trends

Integration of Single-Cell, Spatial and AI-Enabled Multiomic Workflows

High-throughput sequencing is shifting biological research from isolated assays toward integrated molecular datasets containing millions to billions of cellular observations. Illumina's emerging workflows combine genomics, epigenomics, transcriptomics and proteomics, including 5-base sequencing, high-throughput proteomics and single-cell analysis. Its Connected Multiomics platform entered full release in January 2026 after input from 40 early-access users, illustrating the transition toward cloud-based integration and AI-assisted interpretation.

Indian adoption is similarly moving toward higher-resolution research. The country's first Single Cell Omics Translational Research Laboratory was inaugurated at IIT Madras in 2025 with an INR 10.83 crore grant. Meanwhile, India's bioeconomy grew 9.7% in 2024 to USD 165.7 billion and contained 10,075 biotechnology startups, expanding the addressable research ecosystem for sequencing, proteomics and computational platforms.

India Multiomics Market Drivers

Population Genomics and Precision Healthcare Accelerate Molecular Profiling

India's expanding genomic infrastructure is creating large datasets suitable for downstream transcriptomic, proteomic and biomarker integration. GenomeIndia made 10,000 whole genomes accessible through national data infrastructure in 2025, while India's bioeconomy expanded at a reported 17.9% CAGR over the preceding four years. The National Biopharma Mission has also supported 100+ projects and 30 MSMEs through a USD 250 million program, improving translational capacity across therapeutics, diagnostics and biomarker research.

India Multiomics Market Restraints

High Data Complexity and Infrastructure Requirements Limit Broad Clinical Deployment

Integrated experiments can generate millions of molecular measurements and require substantial sequencing, mass-spectrometry, storage and computational resources. Despite India's 10,000-genome national dataset and biotechnology ecosystem exceeding 10,000 startups, simultaneous multi-layer analysis remains more technically demanding than conventional single-omics workflows. BioResearch/BioServices represents only around 9.4% of India's USD 165.7 billion bioeconomy, indicating a smaller specialized research base relative to BioIndustrial at 47.2% and BioPharma at 35.2%.

India Multiomics Market Opportunities

Precision Oncology and Biomarker Programs Create High-Value Research Opportunities

Oncology provides a major pathway for integrating genomic mutations with RNA expression, proteins and therapeutic response. In 2026, IIT Madras launched India's first genome database covering 3 cancer types—leukemia, colorectal and pancreatic cancer—within an initiative supported by INR 56 crore in funding. Reported cancer incidence has risen 12.8% annually since 2022, with more than 2.5 million Indians affected, strengthening the case for molecular biomarkers and personalized therapeutic development.

Challenges in India Multiomics Market

Standardization, Interpretation and Affordable Translation Remain Critical

Moving complex molecular datasets into routine healthcare requires reproducible workflows, interoperable software and affordable testing. Basic genetic testing has reportedly cost around INR 10,000, while proposed sub-INR 1,000 tests illustrate the magnitude of cost reduction being pursued. At the research level, national infrastructure already encompasses 10,000 genomes, yet converting datasets containing billions of nucleotide positions into clinically actionable multi-layer interpretations remains computationally intensive.

India Multiomics Market Segmentation

The industry is segmented by omics type, application, technology, offering, and end user. Genomics holds approximately 27.9% of 2026 revenue, while drug discovery and development represents approximately 25.1% of application revenue.

By Omics Type

Genomics leads at USD 31.18 million in 2026, increasing to USD 98.07 million by 2034 at a 15.40% CAGR. Its leadership reflects extensive use of sequencing in population genetics, oncology, rare diseases, and pharmacogenomics.

Proteomics is the fastest-growing category at 16.44% CAGR, increasing from USD 24.39 million to USD 82.43 million. Transcriptomics follows closely at 16.40%, while lipidomics, epigenomics, metabolomics, and microbiomics record CAGRs of 15.92%, 15.81%, 15.78%, and 15.76%, respectively.

By Application

Drug discovery and development dominates with USD 28.09 million in 2026 and is projected to reach USD 94.22 million by 2034, registering 16.33% CAGR. Biomarker identification is the second-largest application at USD 21.25 million in 2026.

Drug discovery and development is also the fastest-growing listed application at 16.33% CAGR, followed by biomarker identification at 16.18% and systems biology research at 16.11%. Clinical diagnostics advances at 16.04%, while precision medicine and personalized therapy record a 15.18% CAGR.

By Technology

Next-generation sequencing remains a foundational technology because 10,000 Indian whole-genome samples are already available through national genomic infrastructure. Mass spectrometry supports proteomic and metabolomic workflows, while single-cell technologies are gaining institutional capacity through the INR 10.83 crore IIT Madras SCOT laboratory.

Technology convergence increasingly combines NGS, mass spectrometry, microarrays, real-time PCR, single-cell analysis, and integration platforms. Cloud software capable of combining 5+ molecular modalities reduces fragmented analysis and supports datasets extending from millions toward billions of cellular observations.

By Offering

Software and services benefit from expanding data intensity as laboratories integrate 2 or more omics layers per project. Instruments remain capital-intensive, while consumables generate recurring requirements across sequencing and mass-spectrometry workflows; India's biotechnology ecosystem surpassed 10,000 startups by 2024.

Cloud integration and AI interpretation are increasing software importance. Illumina's platform incorporated feedback from 40 early-access users, while India's national genomic infrastructure already supports access to 10,000 genomes, highlighting growing requirements for scalable analytics and data management.

By End User

Pharmaceutical and biotechnology companies represent a central commercial user group, supported by India's bio-pharma sector, which accounted for approximately 35.2% of the USD 165.7 billion bioeconomy in 2024. Academic institutions remain critical to national sequencing and single-cell programs.

CROs, hospitals, and government agencies are expanding applications in biomarker validation, clinical diagnostics, and infectious-disease surveillance. The National Biopharma Mission's support for 100+ projects and 30 MSMEs demonstrates the breadth of translational users connecting research with commercialization.

India Multiomics Market Outlook

South India

Applying the broader Indian bioeconomy's 45.4% southern regional contribution as an ecosystem indicator—not a direct multiomics revenue allocation—South India has the strongest biotechnology concentration. On the supplied 2026 total of USD 111.87 million, an equivalent proportional reference would be approximately USD 50.79 million. Bengaluru and Chennai benefit from biotechnology, single-cell and genomic research infrastructure.

West India

The broader bioeconomy assigns the West 30.3%, equivalent to USD 50.2 billion in 2024; an equivalent proportional reference against the supplied 2026 total would be USD 33.90 million. North India accounts for 18.5%, equivalent to a proportional reference of USD 20.69 million, while East India represents 5.8%, or approximately USD 6.49 million on the same reference basis. These figures are ecosystem-based allocations, not reported regional multiomics revenues.

Top players in India Multiomics Market

1. Illumina, Inc.
2. Thermo Fisher Scientific Inc.
3. Agilent Technologies, Inc.
4. QIAGEN N.V.
5. Bruker Corporation
6. Bio-Rad Laboratories, Inc.
7. 10x Genomics, Inc.
8. Oxford Nanopore Technologies plc
9. Waters Corporation
10. SCIEX
11. Strand Life Sciences
12. MedGenome
13. Premas Life Sciences
14. MapmyGenome
15. Eurofins Scientific

Top Two Companies

• Illumina

Estimated competitive positioning is supported by NGS instruments, informatics and integrated multiomic software rather than a disclosed India-specific percentage. Its Connected Multiomics release incorporates genomics, transcriptomics, proteomics and epigenetics and entered commercial release in 2026 after engagement with 40 early-access users. Its India summit operated across 2 cities—Delhi and Bengaluru—in May 2026, reflecting active ecosystem development. No verifiable India-specific company percentage is publicly disclosed; therefore, assigning a numerical competitive percentage would be speculative.

• Thermo Fisher Scientific

The company maintains broad positioning across sequencing workflows, PCR, mass spectrometry, reagents and laboratory infrastructure, giving it exposure across several multiomic layers. Within an Indian industry expanding at 15.93% CAGR, suppliers spanning instruments, consumables and analytical workflows have structural advantages over single-platform participants. No validated India-specific percentage for Thermo Fisher is available from the supplied dataset or cited public sources; consequently, an unsupported numerical allocation has not been introduced.

Recent Developments in India Multiomics Market

• 2026: Illumina released Connected Multiomics, integrating genomic, transcriptomic, proteomic and epigenetic analysis with AI-supported workflows.
• 2026: India hosted the Multi-Omics Summit 2026 as the country's biotechnology startup ecosystem surpassed 11,000 companies.
• 2026: IIT Madras released India's first genome database covering 3 major cancer types, supported by INR 56 crore in funding.
• 2025: IIT Madras inaugurated India's first Single Cell Omics Translational Research Laboratory with INR 10.83 crore support from IRFC.
• 2025: Uncoded by Premas Life Sciences inaugurated an R&D facility designed to strengthen Indian genomics, transcriptomics, proteomics and metabolomics capabilities.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, historical assessment for 2022–2024, and forecasts through 2034. Supplied numerical tables were treated as the primary authority for industry totals, omics-type values, application values and CAGRs. The model uses USD 96.50 million in 2025, approximately USD 111.87 million in 2026 and USD 365.40 million in 2034, representing 15.93% CAGR. Secondary evidence from government, institutional and company sources was used for ecosystem indicators, technology developments, production proxies and competitive context; calculated percentages were derived directly from supplied values without modifying the underlying data.